The feasibility phase II trial for multidisciplinary therapy for borderline resectable pancreatic cancer.

The feasibility phase II trial for multidisciplinary therapy for borderline resectable pancreatic cancer. - GEM/nPTX & SURGERY trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025416

Enrollment

Registered

2016-12-26

Start date

2016-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Preoperative chemotherapy using GEM/nPTX and panreatectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with pancreatic cancer which is too advanced locally to be resected curatively. 2)The fair or more function of major organs is mainteined. 3)Written informed consent is obtained

Exclusion criteria

Exclusion criteria: 1)Distant metastasis 2)Unresectable local invasion 3)Previous chemotherapy performed within 3 months

Design outcomes

Primary

Measure	Time frame
The postoperative morbidity rate of pancreatectomy following neo-adjuvant GEM/nPTx	—

Countries

Japan

Contacts

Public ContactYosuke Inoue

Ganstointestinal Surgery department, The Cancer Institute Hospital The dept of digestive and HBP surgery

sukeyaubj@yahoo.co.jp0335200111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026